Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
March 14, 2025
by Krebs Qin
A Review of Oncology Biosimilars Products and Companies
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
May 12, 2022
by David Orchard-Webb
2022 — a turning point for US biosimilars?
Cardinal Health says the majority of healthcare providers are keen to use biosimilars despite current market challenges.
February 10, 2022
by CPhIonline
Biologics CDMO market to double in value by 2026, suggests report
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
April 16, 2021
by europeanpharmaceuticalreview
Biosimilars 2020: Low Approvals, but Significant Advances
2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
March 18, 2021
by Neeta Ratanghayra
Global Biosimilars Market Poised to Grow at Chart-topping Levels with a CAGR of 17.3%, Reaching $79.2 Billion by 2026
Frost & Sullivan's recent analysis, Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026, finds that the cost-benefit for end-users (patients) and ease of partnering with specialty contract development and ...
December 11, 2020
by prnasia
Biocon Biologics gets Rs 1, 125 cr capital injection from Goldman Sachs
Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion.
November 9, 2020
by expresspharma
A Comparison of the Biosimilar Accessibility in China, the EU, and the U.S.: China’s Biosimilars Commercialized at an Impressive Speed
Biosimilars significantly reduce patients’ burden and boost the life science innovation to benefit more people!
February 4, 2020
by PharmaSources/1°C
Celltrion, Nan Fung Group form JV to market Biosimilars in China
Vcell Healthcare Limited will obtain the exclusive rights in mainland China to develop, manufacture and commercialize three US FDA and EMA approved biosimilar products from Celltrion
July 20, 2019
by biospectrumasia
British Columbia first province to switch patients to biosimilars
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
May 31, 2019
by europeanpharmaceuticalreview
Surge of Indian biosimilars market forecast in 2019
India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.
April 26, 2019
by cphi-online
Biosimilars that have entered Phase III clinical trials
Biosimilars that have entered Phase III clinical trials
April 23, 2019
by PharmaSources/Caicai